JP2018514557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514557A5 JP2018514557A5 JP2017556740A JP2017556740A JP2018514557A5 JP 2018514557 A5 JP2018514557 A5 JP 2018514557A5 JP 2017556740 A JP2017556740 A JP 2017556740A JP 2017556740 A JP2017556740 A JP 2017556740A JP 2018514557 A5 JP2018514557 A5 JP 2018514557A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- prodrugs
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 89
- 229940002612 prodrug Drugs 0.000 claims description 76
- 239000000651 prodrug Substances 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 52
- 239000012453 solvate Substances 0.000 claims description 52
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 41
- 239000003112 inhibitor Substances 0.000 claims description 14
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 10
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- SAXKEWRSGLPYPB-UHFFFAOYSA-N 2-(1-hydroxyethyl)benzo[f][1]benzofuran-4,9-dione Chemical group O=C1C2=CC=CC=C2C(=O)C2=C1OC(C(O)C)=C2 SAXKEWRSGLPYPB-UHFFFAOYSA-N 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000011443 conventional therapy Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 238000002626 targeted therapy Methods 0.000 claims description 4
- RPCXZIRGAHYOKZ-UHFFFAOYSA-N 2-acetyl-7-fluorobenzo[f][1]benzofuran-4,9-dione Chemical compound O=C1C2=CC(F)=CC=C2C(=O)C2=C1OC(C(=O)C)=C2 RPCXZIRGAHYOKZ-UHFFFAOYSA-N 0.000 claims description 2
- -1 2-acetylnaphtho [2 Chemical compound 0.000 claims description 2
- QORFLTDEUGKOSZ-UHFFFAOYSA-N 2-ethylbenzo[f][1]benzofuran-4,9-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(CC)=C2 QORFLTDEUGKOSZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000003236 esophagogastric junction Anatomy 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 206010073373 small intestine adenocarcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 36
- 238000011069 regeneration method Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087483A JP2021121629A (ja) | 2015-04-27 | 2021-05-25 | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153385P | 2015-04-27 | 2015-04-27 | |
| US62/153,385 | 2015-04-27 | ||
| PCT/US2016/029328 WO2016176190A1 (en) | 2015-04-27 | 2016-04-26 | Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087483A Division JP2021121629A (ja) | 2015-04-27 | 2021-05-25 | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514557A JP2018514557A (ja) | 2018-06-07 |
| JP2018514557A5 true JP2018514557A5 (enExample) | 2019-04-25 |
Family
ID=56081544
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556740A Withdrawn JP2018514557A (ja) | 2015-04-27 | 2016-04-26 | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 |
| JP2021087483A Pending JP2021121629A (ja) | 2015-04-27 | 2021-05-25 | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021087483A Pending JP2021121629A (ja) | 2015-04-27 | 2021-05-25 | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20180250261A1 (enExample) |
| EP (1) | EP3288552A1 (enExample) |
| JP (2) | JP2018514557A (enExample) |
| KR (1) | KR20170141716A (enExample) |
| CN (1) | CN107683137A (enExample) |
| AU (1) | AU2016255034A1 (enExample) |
| BR (1) | BR112017022958A2 (enExample) |
| CA (1) | CA2983468A1 (enExample) |
| EA (1) | EA201792320A1 (enExample) |
| HK (1) | HK1252172A1 (enExample) |
| IL (1) | IL255023A0 (enExample) |
| MX (1) | MX2017013816A (enExample) |
| PH (1) | PH12017501882A1 (enExample) |
| SG (1) | SG11201708506QA (enExample) |
| TW (1) | TW201713329A (enExample) |
| WO (1) | WO2016176190A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027443T2 (en) | 2007-09-10 | 2016-10-28 | Boston Biomedical Inc | A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors |
| JP6433085B2 (ja) | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル， インコーポレイテッド | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン |
| WO2018005444A2 (en) * | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| US11299469B2 (en) | 2016-11-29 | 2022-04-12 | Sumitomo Dainippon Pharma Oncology, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| WO2018213424A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2022178957A1 (zh) * | 2021-02-25 | 2022-09-01 | 毕庶壮 | Napabucasin的制药用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299106B2 (en) * | 2007-09-06 | 2012-10-30 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
| HUE027443T2 (en) * | 2007-09-10 | 2016-10-28 | Boston Biomedical Inc | A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors |
| JP6433085B2 (ja) * | 2013-04-09 | 2018-12-05 | ボストン バイオメディカル， インコーポレイテッド | がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン |
-
2016
- 2016-04-26 CA CA2983468A patent/CA2983468A1/en not_active Abandoned
- 2016-04-26 AU AU2016255034A patent/AU2016255034A1/en not_active Abandoned
- 2016-04-26 SG SG11201708506QA patent/SG11201708506QA/en unknown
- 2016-04-26 US US15/569,236 patent/US20180250261A1/en not_active Abandoned
- 2016-04-26 BR BR112017022958A patent/BR112017022958A2/pt not_active Application Discontinuation
- 2016-04-26 HK HK18111573.2A patent/HK1252172A1/zh unknown
- 2016-04-26 EP EP16725260.0A patent/EP3288552A1/en not_active Withdrawn
- 2016-04-26 WO PCT/US2016/029328 patent/WO2016176190A1/en not_active Ceased
- 2016-04-26 JP JP2017556740A patent/JP2018514557A/ja not_active Withdrawn
- 2016-04-26 MX MX2017013816A patent/MX2017013816A/es unknown
- 2016-04-26 CN CN201680032224.8A patent/CN107683137A/zh active Pending
- 2016-04-26 EA EA201792320A patent/EA201792320A1/ru unknown
- 2016-04-26 KR KR1020177032743A patent/KR20170141716A/ko not_active Withdrawn
- 2016-04-27 TW TW105113235A patent/TW201713329A/zh unknown
-
2017
- 2017-10-15 IL IL255023A patent/IL255023A0/en unknown
- 2017-10-18 PH PH12017501882A patent/PH12017501882A1/en unknown
-
2021
- 2021-05-25 JP JP2021087483A patent/JP2021121629A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514557A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2015520753A5 (enExample) | ||
| JP2022145800A (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| JP2016525097A5 (enExample) | ||
| AU2016247319A1 (en) | Methods for treating cancer | |
| JP2018519324A5 (enExample) | ||
| JP2021121629A (ja) | Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法 | |
| JP2019506392A (ja) | がんを処置するための方法 | |
| JP2019519573A (ja) | がんを処置するための方法 | |
| WO2018213424A1 (en) | Methods for treating cancer | |
| AU2016249157A1 (en) | Methods for treating cancer | |
| JP2018511642A5 (enExample) | ||
| FR3047665B1 (fr) | Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees | |
| JP2024123152A (ja) | 化学療法難治性がんの治療のための新しい併用薬方法 | |
| JP7789016B2 (ja) | 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 | |
| JP2018526377A5 (enExample) | ||
| KR102587702B1 (ko) | 종양 치료제 | |
| TH2001003485A (th) | ไพริโดไพริมิดิโนนชนิดถูกแทนที่ด้วยเบนซิลอะมิโนชนิดใหม่ และอนุพันธ์ในรูปตัวยับยั้ง sos1 | |
| CN115279377A (zh) | 联合疗法 | |
| EA046190B1 (ru) | Новое комбинированное решение для лечения рака, резистентного к химиотерапии | |
| HK40047114A (en) | New combination solution for treating chemotherapy refractory cancer | |
| WO2019230679A1 (ja) | 抗腫瘍剤及び腫瘍治療方法 | |
| KR20210060465A (ko) | 아실티오우레아 화합물과 아비라테론의 병용 요법 | |
| JP2018526375A5 (enExample) |